-
Sector Analysis
Amyotrophic Lateral Sclerosis (ALS) – Opportunity Analysis and Forecasts to 2029
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron degenerative disease which affects both upper motor neurons (UMN) and lower motor neurons (LMN). It is a progressive disease, with patients becoming increasingly dependent on carers and physicians as time from onset increases, and ultimately, it is fatal. ALS can be split into two origins, hereditary - which is known as FALS (Familial ALS) or idiopathic - known as SALS (sporadic ALS). ALS current treatment includes only two disease-modifying drugs: Sanofi’s Rilutek...
-
Thematic Analysis
The State of Personalized/Precision Medicine
Personalized/Precision medicine is a field of medicine that uses information about a person’s genes, proteins, and environment to prevent, diagnose, and treat diseases. In cancer, personalized medicine uses specific information about an individual to help diagnose, plan treatment, find out how well treatment is working, or make a prognosis. The state of personalized/precision medicines market research report covers current and future challenges for the development and launch of these medicines.
-
Sector Analysis
Stem Cells in Neurology
Stem cells in neurology is an evolving field. The current pipeline of products feature different types of stem cells and these therapies have the potential to target a range of neurological diseases. However, there are challenges associated with the development of these therapies, including the need to demonstrate strong safety and efficacy data. Biotechnology companies currently dominate in this field and are expected to lead the development of different pipeline products. The current pipeline consists of 16 products (Phase 1,2,...
-
Sector Analysis
Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron degenerative disease which affects both upper motor neurons (UMN) and lower motor neurons (LMN). It is a progressive disease, with patients becoming increasingly dependent on carers and physicians as time from onset increases, and ultimately, it is fatal. ALS can be split into two origins, hereditary – which is known as FALS (Familial ALS) or idiopathic – known as SALS (sporadic ALS). Currently there are only two drugs on the market that...
-
Product Insights
Alzheimer’s Disease Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Alzheimer's Disease Global Clinical Trials Review, H1, 2017" provides an overview of Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017" provides an overview of Amyotrophic Lateral Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H2, 2016" provides an overview of Amyotrophic Lateral Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...